Business Description
Lumos Diagnostics Holdings Ltd
NAICS : 339112
SIC : 3845
ISIN : AU0000157091
Share Class Description:
FRA:7YU: Ordinary SharesDescription
Lumos Diagnostics Holdings Ltd is engaged in selling Products and providing Services to customers. Its product offering includes rapid, point-of-care diagnostic test products, mainly focused on the diagnosis and management of infectious diseases. Its product is FebriDx, a point-of-care test for detecting and differentiating viral and bacterial respiratory infections. Its Service offering includes contract research and development services specialising in innovation, development, manufacturing and commercialisation of point-of-care diagnostic test solutions. The Company has one operating segment, being the provision of point-of-care diagnostics goods and services. It operates in the United States and Australia, with the majority of revenue generated from the United States.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.6 | |||||
Equity-to-Asset | 0.56 | |||||
Debt-to-Equity | 0.26 | |||||
Debt-to-EBITDA | -5.88 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | -0.94 | |||||
Beneish M-Score | -4.68 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -28.5 | |||||
3-Year EBITDA Growth Rate | 67.5 | |||||
3-Year EPS without NRI Growth Rate | 26.3 | |||||
3-Year FCF Growth Rate | 62.7 | |||||
3-Year Book Growth Rate | -7.5 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 27.18 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 49.76 | |||||
9-Day RSI | 43.6 | |||||
14-Day RSI | 45.38 | |||||
3-1 Month Momentum % | 19.83 | |||||
6-1 Month Momentum % | -55.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.52 | |||||
Quick Ratio | 1.4 | |||||
Cash Ratio | 1.19 | |||||
Days Inventory | 75.34 | |||||
Days Sales Outstanding | 36.26 | |||||
Days Payable | 162.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -42 | |||||
Shareholder Yield % | -20.89 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 60.32 | |||||
Operating Margin % | -106.69 | |||||
Net Margin % | -38.63 | |||||
EBITDA Margin % | -7.46 | |||||
FCF Margin % | -11.72 | |||||
OCF Margin % | 7.65 | |||||
ROE % | -44.8 | |||||
ROA % | -18.35 | |||||
ROIC % | -58.3 | |||||
3-Year ROIIC % | -83.51 | |||||
ROC (Joel Greenblatt) % | -53.98 | |||||
ROCE % | -20.93 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 4.38 | |||||
PB Ratio | 3.09 | |||||
Price-to-Operating-Cash-Flow | 105 | |||||
EV-to-EBIT | -16.65 | |||||
EV-to-EBITDA | -59.84 | |||||
EV-to-Revenue | 4.46 | |||||
EV-to-FCF | -40.54 | |||||
Price-to-GF-Value | 5.2 | |||||
Earnings Yield (Greenblatt) % | -6.01 | |||||
FCF Yield % | -2.14 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lumos Diagnostics Holdings Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 11.364 | ||
| EPS (TTM) (€) | -0.005 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 45.38 | ||
| 14-Day ATR (€) | 0.001699 | ||
| 20-Day SMA (€) | 0.054675 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 0.0385 - 0.178 | ||
| Shares Outstanding (Mil) | 945.12 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lumos Diagnostics Holdings Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lumos Diagnostics Holdings Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2025 | 2025-04-22 | -- | ||
| Second quarter earnings results for 2025 | 2025-01-30 | -- | ||
| General meeting for 2024 | 2024-11-01 09:00 | -- | ||
| First quarter earnings results for 2025 | 2024-10-30 | -- |
Show
Entries
Lumos Diagnostics Holdings Ltd Frequently Asked Questions
What is Lumos Diagnostics Holdings Ltd(FRA:7YU)'s stock price today?
The current price of FRA:7YU is €0.05. The 52 week high of FRA:7YU is €0.18 and 52 week low is €0.04.
When is next earnings date of Lumos Diagnostics Holdings Ltd(FRA:7YU)?
The next earnings date of Lumos Diagnostics Holdings Ltd(FRA:7YU) is .
Does Lumos Diagnostics Holdings Ltd(FRA:7YU) pay dividends? If so, how much?
Lumos Diagnostics Holdings Ltd(FRA:7YU) does not pay dividend.
Press Release
Articles on Lumos Diagnostics Holdings Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers